|Q1 2019 (estimate)
||Decision on whether to issue a statement of objections for certain alleged anti-competitive agreements and/or concerted practices and certain parties
|July 2018 to Q1 2019
||Further investigation including further information gathering in relation to certain alleged anti-competitive agreements and/or concerted practices and certain parties. CMA analysis and review of information gathered.
|October 2017 to June 2018
||Initial investigation and information gathering. CMA analysis and review of information gathered.
On 10 October 2017, the CMA launched an investigation under Chapter 1 of the CA98 and Article 101 of the TFEU into suspected breaches of competition law by various parties. The investigation relates to alleged anti-competitive agreements and/or concerted practices in relation to generic pharmaceutical products.
The CMA has not reached a view on whether there is sufficient evidence of an infringement of competition law for it to issue a statement of objections to the parties under investigation. Not all cases result in the CMA issuing a statement of objections.
Assistant Project Director
Maria Rican-Sevitz (020 3738 6859, firstname.lastname@example.org)
Geoff Steadman (020 3738 6311, email@example.com)
Senior Responsible Officer
Ann Pope (020 3738 6786, firstname.lastname@example.org)